伊马替尼对一名转移性莱迪希细胞瘤患者无效。

Lack of efficacy of imatinib in a patient with metastatic Leydig cell tumor.

作者信息

Froehner Michael, Beuthien-Baumann Bettina, Dittert Dag-Daniel, Schuler Ulrich, Wirth Manfred P

机构信息

Department of Urology, University Hospital, Technical University of Dresden, Fetscherstrasse 74, 01307, Dresden, Germany.

出版信息

Cancer Chemother Pharmacol. 2006 Nov;58(5):716-8. doi: 10.1007/s00280-005-0181-6. Epub 2006 Feb 1.

DOI:10.1007/s00280-005-0181-6

PMID:16450163

Abstract

Imatinib is a tyrosine kinase inhibitor with activity in gastrointestinal stromal tumor and a variety of other solid and hematological malignancies. Studies in vitro and in a mouse model suggested that the imatinib might also be active in malignant Leydig cell tumor. We report on the--to our knowledge--first treatment experiment with imatinib in a patient with metastatic Leydig cell tumor. Unfortunately, the tumor progressed during treatment.

摘要

伊马替尼是一种酪氨酸激酶抑制剂，对胃肠道间质瘤以及多种其他实体和血液系统恶性肿瘤具有活性。体外研究和小鼠模型研究表明，伊马替尼可能对恶性间质细胞瘤也有活性。据我们所知，我们报告了首例对转移性间质细胞瘤患者使用伊马替尼的治疗实验。不幸的是，肿瘤在治疗期间进展。